RAMES study: is there really a role for VEGF inhibition in mesothelioma?

Affiliations

¹ Department of Biomedical Sciences and Human Oncology, University of Bari A Moro, Bari, Italy.
² Department of Precision Oncology, University Hospital of Campania L Vanvitelli, 80138 Naples, Italy. Electronic address: valerio.nardone@unicampania.it.
³ Department of Clinical Medicine, Trinity Centre for Health Sciences, Trinity Translational Medicine Institute, St James's Hospital and Trinity College, Dublin, Ireland.
⁴ Medical Oncology Unit, Grand Metropolitan Hospital Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
⁵ Italian Group for Research and Therapy for Mesothelioma (GIMe), Voghera, Italy.

Comment

Camillo Porta et al. Lancet Oncol. 2021 Dec.

. 2021 Dec;22(12):e532.

doi: 10.1016/S1470-2045(21)00640-9.

¹ Department of Biomedical Sciences and Human Oncology, University of Bari A Moro, Bari, Italy.
² Department of Precision Oncology, University Hospital of Campania L Vanvitelli, 80138 Naples, Italy. Electronic address: valerio.nardone@unicampania.it.
³ Department of Clinical Medicine, Trinity Centre for Health Sciences, Trinity Translational Medicine Institute, St James's Hospital and Trinity College, Dublin, Ireland.
⁴ Medical Oncology Unit, Grand Metropolitan Hospital Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
⁵ Italian Group for Research and Therapy for Mesothelioma (GIMe), Voghera, Italy.

No abstract available

Conflict of interest statement

We declare no competing interests.

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL. Pinto C, et al. Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6. Lancet Oncol. 2021. PMID: 34499874 Clinical Trial.
RAMES study: is there really a role for VEGF inhibition in mesothelioma? - Authors' reply.
Zucali PA, Pinto C, Ceresoli GL; RAMES investigators. Zucali PA, et al. Lancet Oncol. 2021 Dec;22(12):e533. doi: 10.1016/S1470-2045(21)00666-5. Lancet Oncol. 2021. PMID: 34856143 No abstract available.